SaxoCell Cluster
SaxoCell aims to develop new areas of application and production methods for personalized gene and cell therapeutics, so-called »living drugs«. The aim is to produce cells with precisely defined functions and a high safety profile for safe, clinical use on an industrial scale and at socially acceptable costs in order to enable a realistic and sustainable economic model with high value-added potential for the region.
In order to achieve this aim, four of the best research institutions in Saxony have joined forces:
TU Dresden
Universität Leipzig
Fraunhofer Institute for Cell Therapy and Immunology
Klinikum Chemnitz
Cluster4Future Innovation Competition
SaxoCell is one of the winners of the innovation competition “Clusters4Future” of the Federal Ministry of Education and Research (BMBF). Our concept for a Saxon future cluster SaxoCell in the promising field of cell and gene therapy was selected by an expert jury together with six other projects from a total of 137 applicants in the first competition phase.
Our Vision
SaxoCell will significantly improve regional networking in Saxony in the field of cell and gene therapy, integrate further partners and initiatives nationwide and close corresponding gaps in the value chains. In this way, synergy potentials will be raised and realized. In addition, the cluster will massively increase the visibility of the activities of Saxon and nationwide partners in the field of cell and gene therapy – both at the level of research and with regard to the R&D activities of industrial partners. Thus, access to funding will be facilitated and expanded for the players, and structures will be created to accelerate clinical implementation (network of clinical players and cooperation with regulatory authorities). Through these and other activities, SaxoCell will thus significantly increase the attractiveness for investments of national and international companies in this industrial sector and contribute substantially to the development and further strengthening of an innovative cell and gene therapy industry in Saxony and Germany.
Long-term goals
Development of novel ATMPs (advanced therapy medicinal products) and expansion of their previous areas of application
Improving the tolerability and efficacy of ATMPs through the latest cell and gene therapy (CGT) technologies
Increasing manufacturing efficiency through automation / artificial intelligence (AI) and standardization
Creation of an innovative preclinical and clinical environment for the optimal development of the industry in Saxony, also through measures of professional education and training
Strengthening regional, national and international technology transfer by attracting investments and innovations from international companies to Saxony
Präzisionstherapie-Cluster
